Transcription
John Ma 0:05
Good afternoon. I am John Ma. I'm the founder and the CEO of Renovo Surgical. I like to present to you the first module of robotic platform called the Carina for laparoscopy from China. And it's designing China and the made for the word. But to start, I have nine minutes, I'd like to show you a video clip and just to warn you that it does contain surgical scenes. This is actually three animal clinical trials that we have recently conducted. You see the system Carina in a typical operating room roughly about 33 square meters. And they you see a procedure on the right, which is nephrectomy, separating renal vessels, you also see the urethra cutting for prostatectomy. And the to the bottom right is vaginal stump that suturing procedure that's performed. I would also like to show you in a typical operating room, modular system that how you configure that which is with a lot of ease, and you give surgeon multiple choices of different docking positions, and also, you know, different setups. So this is obviously very different than what you have seen in the past 20 years. So you must wonder why did we do this. So this is a little bit history. Today in China, the surgical volume is very high that we have we perform about 10 million procedures mis procedures a year. But when you look at the robotic penetration, it's less than 1%. We're talking about a country with 10 million procedures, 10,000 hospitals, over 100,000 surgeons who can perform minimally invasive surgeries. But when you look at the type of surgeries the specialties that you perform the majority of the specialties in general surgery and in gynecology, the robotic penetration is only less than point 5%, which is extremely low. So when the renewable surgical was founded, we believe that we're very laser focused that the solution to a much broader penetration and the utilization of robotic technology lies with being flexible and cost effective. How do you do that, to that we have the idea of developing modular robot, a variety of instruments from straight to rest of the instrument, multi quadrant access is extremely important. And it has to fit with any operating room to be honest. So this is essentially when we set out to the to founded the company that we had in mind. So in the last three years from inception to where we are today that we spent almost a year to validate the clinical needs and performing assessments. And we spent about 10 months from concept design to complete the first alpha prototype and by performing the first animal lab, and then we spend about another 10 months completing beta prototype and spent a majority of our efforts in doing animal trials and perform the first cadaver. So in the 2022, the year we have performed the total 12 Animal labs. What's more important is that we accelerate the pace and the first quarter of 2023 that we have performed the 26 Animal labs which is twice the amount of that we have performed that in 2022 So right now we are clinical ready that completed GLP animal labs and we have also completed the industrial standard type test called the NMPA in China. So we are ready to officially start performing human clinical trials next year. So this is where we stand in current phase as I mentioned before that we are targeting two important special of which is the gynecology and the Urology. This gave us an addressable market about roughly 5 million procedures a year that we were doing that is again that we will provide the configurability to the surgeons that with a three arm to four arm configuration, offering the possibility of a continue to use the straight instrument a five millimeter and also articulated the instrument of 8 millimeter. So this is again the compatible with the hospitals the existing vision system, or we have our own in house developed the three dimensional High High Definition imaging eye with ICG capability as well. Our next phase is we are going to have full coverage that will when we complete the two specialty clinical trial towards the later part of this year, that with the kickoff of two other specialties in general surgery and the thoracic surgery is more capabilities with regards to modular design and the configurability as well as functional capabilities as well. So the thanks to the team that we have established in the three years and we have 140 team member and they are coming from a variety of robotic companies, Intuitive Surgical Oris, and other med tech companies. And we have established a very strong technology collaboration as our advisors from previous leaders from Intuitive Surgical and the Auris. And also we have clinical advisors, both in China and globally. We have already established clinical sites, as I mentioned before for later this year, as well as like a surgical robotic society with the International key opinion leaders. So that we are ready to raise a 30 million Series B. So if you're interested in let's talk I just want to mention also that tomorrow I will be on a panel to talk about specifically the 800 pound gorilla in robotic assisted surgery with the other panel speakers and we'll be very happy to see you there as well. Okay, that's it. Thank you very much.
© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
